Updated: May 27, 2008
Dislocations of the foot are uncommon but potentially incapacitating injuries. The mechanism of injury may vary from a simple fall to a major motor vehicle collision (MVC). The foot is a complex structure, and injuries often occur in patients who sustain multiple trauma. The clinician must understand common patterns of injury and maintain a high index of suspicion in examining the appropriate radiographs to avoid missing foot dislocations.
Anatomy
The foot consists of 26 bones and 57 articulations. The foot is composed of 3 functional and anatomic regions. The hindfoot consists of the talus and the calcaneus. The midfoot consists of the navicular, the cuboid, and the 3 cuneiforms. The forefoot contains the 5 metatarsals and 14 phalanges.
The foot also contains numerous accessory centers of ossification that are occasionally mistaken for avulsion injuries. The presence of a smooth cortical surface and lack of associated soft-tissue edema helps to differentiate these normal variants from fractures.
The articulations between the hindfoot and the midfoot are the midtarsal or Chopart joints. These joints are the talonavicular and the calcaneocuboid joints. The articulations between the midfoot and the forefoot are termed the Lisfranc joints and consist of the 5 tarsometatarsal joints.
The subtalar joint, between the talus and the calcaneus, accounts for most inversion and eversion injuries to the hindfoot. Adduction and abduction of the forefoot primarily occurs through the midtarsal joints. Flexion and extension primarily occurs at the metatarsophalangeal (MTP) and interphalangeal (IP) joints.
All dislocations in the foot (with the exception of simple dislocations of the toes) are uncommon injuries. The most common of these injuries is a dislocation that involves the Lisfranc joint complex. The rarity of these injuries makes diagnosis difficult. A significant proportion of the more subtle dislocations are not diagnosed upon initial presentation. Dislocations through the Lisfranc joint complex are thought to have an incidence of about 1 in 50,000 persons with orthopedic trauma per year, representing fewer than 1% of all dislocations.
No information is available on international injury rates.
Dislocations of the foot are commonly associated with other significant injuries sustained during falls or MVCs. Delay in recognition of dislocations is common because of the distracting effect of the associated injuries or because of the subtle nature of these injuries. Early reduction and immobilization may reduce morbidity.
Many complications, including avascular necrosis, compartment syndrome, and degenerative arthritis, have been reported. Additionally, residual pain and loss of function is a common consequence of the complex biomechanics of the foot.
The male-to-female ratio is 6:1. This differential is largely due to the higher number of young males who sustain significant trauma.
Injury may occur at any age, although the more severe forms of dislocation associated with MVCs are more common in young adult males.
Both a detailed medical history and a history of the events surrounding the injury or appearance of symptoms are essential in identifying the type of injury and predisposition to complicating factors.
The history should include the following questions:
In general, patients who experience dislocations of the foot have other injuries related to the mechanism of injury. A full history of the event should be obtained from the patient or prehospital caregivers. Occasionally, these injuries may occur with minimal trauma. This is especially true with athletes. The history in these cases is usually of increasing pain and edema over a few days, resulting in a significant limitation of mobility, decreased performance, or both. Often, the patient gives no definitive history of a single traumatic event. The presumed mechanism of injury responsible for each type of dislocation is discussed with that dislocation.
Examination of the foot usually reveals an obvious deformity; however, some dislocations are accompanied by substantial soft-tissue edema. The exact nature of the injury may be unclear until radiography is performed.
The risk factors for dislocation of the foot are the same as those for any major trauma (ie, youth, alcohol intake, drug intake). However, dislocations of the foot can result from an apparently simple fall (eg, twisting one's foot in a hole in the ground when jogging).
Numerous different types of dislocations of the foot are recognized. These dislocation types are discussed below with a review of their causes as follows:
Ankle Injury, Soft Tissue
Compartment Syndrome, Extremity
Dislocations, Ankle
Dislocations, Interphalangeal
Fractures, Ankle
Fractures, Foot
Administer analgesia as appropriate. Ensure adequate coverage against tetanus. If dislocation is compound, broad-spectrum intravenous antibiotics are required. Generally, a cephalosporin is the drug of choice. Dirty wounds may need the addition of an aminoglycoside to target gram-negative organisms. Injuries heavily contaminated with soil or farmyard waste require penicillin to protect against Clostridium perfringens.
Pain control is essential to quality patient care. It ensures patient comfort, promotes pulmonary toilet, and aids physical therapy regimens. Many analgesics have sedating properties that benefit patients who have sustained injuries.
More potent narcotic analgesic with much shorter half-life than morphine sulfate. DOC for conscious sedation analgesia.
With short duration (30-60 min) and easy titration, excellent choice for pain management and sedation. Easily and quickly reversed by naloxone.
After initial dose, subsequent doses should not be titrated more frequently than q3h or q6h.
0.5-1 mcg/kg/dose IV/IM q30-60 min
<2 years: 2-3 mcg/kg/dose IV/IM q30-60min
2-12 years: 1-2 mcg/kg/dose IV/IM q60min
>12 years: Administer as in adults
Phenothiazines may antagonize analgesic effects; tricyclic antidepressants may potentiate adverse effects
Documented hypersensitivity; hypotension; potentially compromised airway in which establishing rapid airway control would be difficult
C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
Caution in hypotension, respiratory depression, constipation, nausea, emesis, and urinary retention; idiosyncratic reaction, known as chest wall rigidity syndrome, may require neuromuscular blockade in order to increase ventilation
Drug combination indicated for relief of moderately severe to severe pain. DOC for aspirin-hypersensitive patients.
1-2 tab or cap PO q4-6h prn
0.05-0.15 mg/kg/dose oxycodone PO q4-6h prn; not to exceed 5 mg/dose of oxycodone
Phenothiazines may decrease analgesic effects; CNS depressants or tricyclic antidepressants increase toxicity
Documented hypersensitivity
C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
Duration of action may increase in elderly persons; be aware of total daily dose of acetaminophen patient is receiving; do not exceed 4000 mg/24 h of acetaminophen; higher doses may cause liver toxicity
Drug combination indicated for relief of moderately severe to severe pain.
1-2 tab or cap PO q4-6h prn
0.05-0.15 mg/kg/dose oxycodone PO q4-6h prn; not to exceed 5 mg/dose of oxycodone
Phenothiazines may decrease analgesic effects; CNS depressants or tricyclic antidepressants increase toxicity; may potentiate anticoagulant effects of warfarin
Documented hypersensitivity; liver damage; hypoprothrombinemia; vitamin K deficiency; bleeding disorders; asthma
Because of association with Reye syndrome, not for use in children (<16 y) who have flu
D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus
Duration of action may increase in elderly persons; caution in renal or liver impairment, peptic ulcer disease, and erosive gastritis
Drug combination indicated for relief of moderately severe to severe pain.
1-2 tab or cap PO q4-6h prn
<12 years: 10-15 mg/kg/dose acetaminophen PO q4-6h prn; not to exceed 2.6 g/d acetaminophen or 5 mg of hydrocodone bitartrate/dose
>12 years: 750 mg acetaminophen PO q4h; not to exceed 5 doses/d acetaminophen or 10 mg of hydrocodone bitartrate/dose
Phenothiazines may decrease analgesic effects; CNS depressants or tricyclic antidepressants increase toxicity
Documented hypersensitivity; high-altitude cerebral edema; elevated intracranial pressure
C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
Tablets contain metabisulfite, which may cause hypersensitivity; caution in patients dependent on opiates since this substitution may result in acute opiate withdrawal symptoms; caution in severe renal or hepatic dysfunction
Patients with painful injuries usually experience significant anxiety. Anxiolytics allow the clinician to administer a smaller analgesic dose to achieve the same effect.
DOC for procedural sedation to aid in reduction of anxiety associated with fractures or dislocations. Provides antegrade amnesia. Dose q1-2h.
1 mg IV slowly q2-3min
<6 months: Not established
6 months to 6 years: 0.05-0.1 mg/kg IV; not to exceed total dose of 0.6 mg/kg
6-12 years: 0.025-0.05 mg/kg IV; not to exceed total dose of 0.4 mg/kg
>12 years: Administer as in adults
Sedative effects may be antagonized by theophyllines; narcotics and erythromycin may accentuate sedative effects due to decreased clearance
Documented hypersensitivity; preexisting hypotension; narrow-angle glaucoma; sensitivity to propylene glycol (diluent)
D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus
Caution in congestive heart failure, pulmonary disease, renal impairment, and hepatic failure
Procedural sedation for reductions may require a sedative hypnotic.
Phenolic compound. Sedative hypnotic agent used for induction and maintenance of sedation or anesthesia.
Procedural sedation: 0.5 mg/kg IV infused over 3-5 min initially
Procedural sedation: 0.5-1 mg/kg IV push infused over 2 min initially
Reduce propofol dose when administered concomitantly with benzodiazepines, opiates, phenothiazines, ethanol, and narcotics; propofol may potentiate neuromuscular blockade of vecuronium; theophylline may weaken effects of propofol, and dose increase may be needed
Documented hypersensitivity to propofol or allergy to soybean oil, egg yolk, glycerol, or disodium edentate
B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
Patients may develop apnea and may experience a decrease in systemic vascular resistance leading to hypotension
Do not administer with blood or blood products using same IV catheter
Prophylaxis is given to patients with compound dislocations.
First-generation semisynthetic cephalosporin that binds to one or more penicillin-binding proteins, arrests bacterial cell wall synthesis, and inhibits bacterial replication. Primarily active against skin flora, including Staphylococcus aureus. Total daily dosages are same for IV and IM routes.
2 g IV/IM; not to exceed 12 g/d
25-100 mg/kg/d IV/IM; not to exceed 6 g/d
Probenecid prolongs effect; aminoglycosides may increase renal toxicity; may yield false-positive urine dip test result for glucose
Documented hypersensitivity
B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
Adjust dose in renal impairment; superinfections and promotion of nonsusceptible organisms may occur with prolonged use or repeated therapy
Aminoglycoside antibiotic used for gram-negative bacterial coverage. Commonly used in combination with both an agent against gram-positive organisms and one that covers anaerobes.
Used in conjunction with ampicillin or vancomycin for prophylaxis in patients with compound dislocations. Dosing regimens numerous and adjusted based on CrCl and changes in volume of distribution. May be given IV or IM.
1.5 mg/kg IV; not to exceed 80 mg
<5 years with normal renal function: 2.5 mg/kg/dose IV/IM q8h
>5 years: 1.5-2.5 mg/kg/dose IV/IM q8h or 6-7.5 mg/kg/d IV/IM divided q8h
Other aminoglycosides, cephalosporins, penicillins, and amphotericin B may increase nephrotoxicity; enhance effects of neuromuscular blocking agents, thus prolonged respiratory depression may occur; loop diuretics may increase auditory toxicity; possible irreversible hearing loss of varying degrees may occur (monitor regularly)
Documented hypersensitivity; non–dialysis-dependent renal insufficiency
C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
Narrow therapeutic index (not intended for long-term therapy); caution in renal failure (not on dialysis), myasthenia gravis, hypocalcemia, and conditions that depress neuromuscular transmission; adjust dose in renal impairment
Potent antibiotic directed against gram-positive organisms and active against enterococcal species. Used to treat septicemia and skin-structure infections. Used in conjunction with gentamicin for prophylaxis in patients with penicillin allergy with compound dislocations. May need to adjust dose in patients with renal impairment.
1 g IV infusion over 1 h
Administer as in adults
Erythema, histaminelike flushing, and anaphylactic reactions may occur when administered with anesthetic agents; with aminoglycosides, risk of nephrotoxicity may increase above that with aminoglycoside monotherapy; effects in neuromuscular blockade may be enhanced when coadministered with nondepolarizing muscle relaxants
Documented hypersensitivity
C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus
Caution in renal failure, neutropenia; red man syndrome caused by too rapid IV infusion (dose given over a few minutes) but rarely happens when dose given over 2 h or by PO or IP route; red man syndrome not an allergic reaction
Used along with gentamicin for prophylaxis in patients with compound dislocations. Interferes with bacterial cell wall synthesis during active replication, causing bactericidal activity against susceptible organisms. Given in place of amoxicillin in patients unable to take PO medication.
2 g IV/IM
50 mg/kg IV/IM
Probenecid and disulfiram elevate levels; allopurinol decreases effects and has additive effects on ampicillin rash; may decrease effects of PO contraceptives
Documented hypersensitivity
B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
Adjust dose in renal failure; evaluate rash and differentiate from hypersensitivity reaction
Interferes with synthesis of cell wall mucopeptide during active replication, resulting in bactericidal activity against susceptible microorganisms.
2.4 million U IM as single dose in 2 injection sites
50,000 U/kg IM; maximum of 2.4 million U
Probenecid can increase effects; tetracyclines can decrease effects
Documented hypersensitivity
B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals
Caution in impaired renal function
One of the major complications of dislocations of the foot involves a failure to make the diagnosis. Some of these dislocations can be subtle, especially those around the Lisfranc joint complex. These dislocations often are missed, resulting in significant morbidity.
Englanoff G, Anglin D, Hutson HR. Lisfranc fracture-dislocation: a frequently missed diagnosis in the emergency department. Ann Emerg Med. Aug 1995;26(2):229-33. [Medline].
Brunet JA. Pathomechanics of complex dislocations of the first metatarsophalangeal joint. Clin Orthop Relat Res. Nov 1996;(332):126-31. [Medline].
Bohay DR, Manoli A 2nd. Subtalar joint dislocations. Foot Ankle Int. Dec 1995;16(12):803-8. [Medline].
Perron AD, Brady WJ, Keats TE. Orthopedic pitfalls in the ED: Lisfranc fracture-dislocation. Am J Emerg Med. Jan 2001;19(1):71-5. [Medline].
Davis CA, Lubowitz J, Thordarson DB. Midtarsal fracture-subluxation. Case report and review of the literature. Clin Orthop Relat Res. Jul 1993;(292):264-8. [Medline].
Karasick D. Fractures and dislocations of the foot. Semin Roentgenol. Apr 1994;29(2):152-75. [Medline].
Milenkovic S, Radenkovic M, Mitkovic M. Open subtalar dislocation treated by distractional external fixation. J Orthop Trauma. Oct 2004;18(9):638-40. [Medline].
Mulier T, Reynders P, Sioen W, et al. The treatment of Lisfranc injuries. Acta Orthop Belg. Jun 1997;63(2):82-90. [Medline].
Prokuski LJ, Saltzman CL. Challenging fractures of the foot and ankle. Radiol Clin North Am. May 1997;35(3):655-70. [Medline].
Saab M. Lisfranc fracture--dislocation: an easily overlooked injury in the emergency department. Eur J Emerg Med. Jun 2005;12(3):143-6. [Medline].
Simon JP, Van Delm I, Fabry G. Fracture dislocation of the tarsal navicular. Acta Orthop Belg. 1993;59(2):222-4. [Medline].
Wagner R, Blattert TR, Weckbach A. Talar dislocations. Injury. Sep 2004;35 Suppl 2:SB36-45. [Medline].
foot dislocation, dislocation foot, motor vehicle collision, MVC, hindfoot, talus, calcaneus, midfoot, navicular, cuboid, cuneiforms, forefoot, metatarsals, phalanges, subtalar joint, compartment syndrome, degenerative arthritis, diabetes mellitus, denervation of the foot, Charcot joints, Lisfranc dislocation, subtalar dislocation, peritalar dislocation, isolated fracture dislocation, cuboid fracture, cuneiform fracture, tarsometatarsal dislocation
Christopher M McStay, MD, Assistant Professor, Department of Emergency Medicine, New York University, Bellevue Hospital Center
Christopher M McStay, MD is a member of the following medical societies: American College of Emergency Physicians and Wilderness Medical Society
Disclosure: Nothing to disclose.
Moira Davenport, MD, Attending Physician, Departments of Emergency Medicine and Orthopedic Surgery, Allegheny General Hospital
Moira Davenport, MD is a member of the following medical societies: American College of Emergency Physicians and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.
Martin J Carey, MD, MB, BCh, MPH, FACEM, FRCS, Program Director, Assistant Professor, Department of Emergency Medicine, University of Arkansas for Medical Sciences
Martin J Carey, MD, MB, BCh, MPH, FACEM, FRCS is a member of the following medical societies: American College of Emergency Physicians, American Medical Association, British Medical Association, and Fellowship of the Australasian College for Emergency Medicine
Disclosure: Nothing to disclose.
James E Keany, MD, FACEP, Medical Director, JetWest International Air Ambulance; Consulting Staff, Department of Emergency Services, Mission Hospital Regional Medical Center; Host of The Bodcast at Jim.MD
James E Keany, MD, FACEP is a member of the following medical societies: American College of Emergency Physicians, American College of Sports Medicine, and California Medical Association
Disclosure: Nothing to disclose.
Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.
David B Levy, DO, FACEP, FAAEM, Chairman, Department of Emergency Medicine, St Elizabeth Health Center; Associate Professor of Emergency Medicine, Northeastern Ohio Universities College of Medicine
David B Levy, DO, FACEP, FAAEM is a member of the following medical societies: American Academy of Emergency Medicine, American Medical Informatics Association, and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.
John D Halamka, MD, MS, Associate Professor of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center; Chief Information Officer, CareGroup Healthcare System and Harvard Medical School; Attending Physician, Division of Emergency Medicine, Beth Israel Deaconess Medical Center
John D Halamka, MD, MS is a member of the following medical societies: American College of Emergency Physicians, American Medical Informatics Association, Phi Beta Kappa, and Society for Academic Emergency Medicine
Disclosure: Nothing to disclose.
Rick Kulkarni, MD, Medical Director, Assistant Professor of Surgery, Section of Emergency Medicine, Yale-New Haven Hospital
Rick Kulkarni, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Emergency Medicine, American College of Emergency Physicians, American Medical Association, American Medical Informatics Association, Phi Beta Kappa, and Society for Academic Emergency Medicine
Disclosure: WebMD Salary Employment
© 1994-
by Medscape.
All Rights Reserved
(http://www.medscape.com/public/copyright)